Financial Performance - OnKure Therapeutics reported a net loss of $14.7 million for Q3 2025, compared to a net loss of $11.6 million in Q3 2024, with a net loss per share of $1.09[12] - Research and development expenses increased to $11.9 million in Q3 2025 from $10.1 million in Q3 2024, primarily due to higher personnel-related costs[12] - General and administrative expenses rose to $3.6 million in Q3 2025, up from $1.4 million in Q3 2024, attributed to increased personnel costs and professional service fees[12] - Total operating expenses for Q3 2025 were $15.5 million, compared to $11.5 million in Q3 2024[17] Cash Position - As of September 30, 2025, OnKure had approximately $70.3 million in cash and cash equivalents, expected to fund operations into Q4 2026[12] Clinical Trials - A total of 71 patients have been dosed in the PIKture-01 trial, with 37 in monotherapy and 34 in combination with fulvestrant[7] - The first patients were dosed in triplet expansion arms of the PIKture-01 trial in September and October 2025, with initial data expected in Q1 2026[7] Research and Development - OnKure is advancing its next-generation PI3Ka pan-mutant inhibitor program, with multiple candidates identified and an announcement planned for Q1 2026[1] - The company aims to lead the development of selective PI3Kα inhibitors for breast cancer and rare diseases, focusing on early lines of therapy[2] - The company is expanding into vascular malformations, with further details to be provided in 2026[1]
OnKure Therapeutics, Inc.(OKUR) - 2025 Q3 - Quarterly Results